Search This Blog

Labels

T 1890/15 - Giving oral evidence, or replacing representative's pleading


In the present case, the patent proprietor (appellant) lodged an appeal against the decision of the opposition division revoking the European patent and requests oral submissions of a technical expert as accompanying person to explain the skilled person's understanding. The Board applies the criteria of G 4/95 and concludes that these were not complied with, and exercises its discretion referred to in G 4/95 by not permitting the technical expert as an accompanying person to make oral submissions.

Additionally, the Board deliberates whether the Enlarged Board in G 4/95, and specifically when considering that Art. 117 EPC did not provide a legal basis for hearing oral submissions by an accompanying person involving the presentation of facts and evidence, means that the Enlarged Board considered that an accompanying person, in particular a technical expert, gives oral evidence by way of making oral submissions at the oral proceedings, or merely presents (legal or technical) arguments in place of the presentation of the case (pleading) by the professional representative.

The Board concludes that should oral submissions by an accompanying person be considered and intended to be oral evidence comparable to a written statement ("affidavit") of said person, the same criteria as for the admission of late filed facts and evidence should apply. 

T 0156/15 - Admissibility of expert evidence and tactically filed requests



Does it help to submit an expert opinion regarding added matter in a divisional application (Art. 76(1) EPC), when the expert is a well-known former chair of a technical Board of Appeal and member of the Enlarged Board of Appeal? And how far will the Board go in admitting requests submitted during oral proceedings in response to the Board’s deliberations on previous requests?

European patent No. 2 106 790, based on European patent application No. 09007867.6, was filed as a divisional application of European patent application No. 05728268.3. Opposition to the patent was filed by one opponent. By interlocutory decision of the Opposition Division, the patent in suit was maintained in amended form according to Auxiliary Request 1. This Auxiliary Request 1 only differed from the patent as granted in an amendment introduced in paragraph [0020] of the description. Claim 1 of auxiliary request 1 was identical to claim 1 of the patent as granted, which reads:

"1. A composition, which has been prepared in a solution, comprising a therapeutically effective dose of insulin or insulin derivative, ions of citric acid, and a zinc metal chelator effective to dissociate the insulin into monomers or dimers, in a form suitable for subcutaneous administration".

The amendment to paragraph [0020] of the description resulted in citric acid no longer being listed as a suitable chelator, but only as a solubilising acid, thus arguably rendering the claim novel over prior art document D2.

Both parties appealed the decision. The opponent argued, inter alia, that the patent was not in compliance with Art. 76(1) EPC, as the parent patent nowhere disclosed “ions of” of any acid as solubilising agent.

During oral proceedings, the Board came to the conclusion that by admitting submissions made by a former Board member, however eminent that person might be, it would attach undue weight to the individual making the argument rather than focus on the argument itself. Accordingly, the expert opinion was not admitted into the proceedings – rather, the Board allowed the proprietor to rely on the arguments presented therein merely as his own submissions.

Regardless, the Board found that the Main Request – identical to claim 1 as granted - does not comply with the requirements of Article 76(1) EPC, since it cannot be directly and unambiguously derived from the earlier application that the compositions of claim 1 inevitably contain the ionic form of the acids. Auxiliary requests filed sequentially in response the Board’s deliberation in this matter and on the admissibility of the requests itself were not admitted for lack of prima facie relevance or raising new issues. The Board further stressed that by adjusting its strategy to the results of the Board's deliberation, the proprietor puts the opponent in a position where it is difficult to react. For this reason, in principle, the Board could have refused these requests even without also considering the specific criteria for the exercise of its discretion to admit new auxiliary requests.

The only remaining request not violating Art. 76(1) EPC – i.e., relating to compositions containing an acid in its non-dissociated (no ions) form – then led to an inescapable trap (Art. 123(3) EPC) situation, and the patent was revoked.


T 488/16 - Not plausible at the filing date

Is it plausible that the compound had the effect?

In this opposition appeal the effect (inhibiting PTK activity) of the claimed compound (dasatinib) was supported with post-published documents: documents (9) and (10) filed during the Examination procedure and documents (36) and (37) filed with the statement of the grounds. 

The application as filed contains a large number of compounds of which one is selected in the claim under appeal. The decision does not contest that the post-published documents show that this compound works, indeed works very well. The question is, whether this was plausible at the filing date. The board maintains the revocation of the patent. 


T 1818/12 - On evidence, sufficiency, and effect

This pencil cracked under the pressure

The main claim in this opposition appeal concerns an E. coli host cell sample subjected to non-lysing pressure. According to the opponent the examples in the patent are the only known cell systems that do not lyse under the conditions of the claim, or that give the effect of increased yield. As a result, the claim is neither workable nor inventive over the entire scope claimed. 
The Board has problems with the evidentiary value of the documents cited by the opponent. Furthermore, that there exists an embodiment falling under the scope of the claim that does not show the effect is in itself not enough to deny inventive step. 

T 615/14 - Oops, mistake! Sheer force of habit...but repairable.


In G1/12 it was decided that Rule 139 could be used to correct the appellant's name. The Board of Appeal in the present case decided that such is also applicable to a correction of the opponent's name, although the situation in appeal proceedings is different from that in opposition proceedings because the identity of an appellant is limited to one or only a few options, namely the party or parties involved in first-instance proceedings, while in the case of an opposition the identity of the opponent was completely unknown and in fact could be any party whatsoever. The Board disagreed with this because there was only a choice between two options and not an endless number, which makes that there was no difference between this case and an appeal. The Board further sets out the reasons why a correction under Rule 139, following G1/12, is also applicable to opposition proceedings, and uses the (in the Board's view allowable) post-9 months filed evidence, to come to its final decision that a correction under Rule 139 was allowable here.
Summary of Facts and Submissions
I. This decision concerns the appeal filed by the opponent against the decision of the opposition division to reject the opposition against European patent No. 1 605 772 as inadmissible.
II. On 26 March 2008, professional representative Mr ... for Andries van Westerbrugge et al. / N.V. Nederlands Octrooibureau had filed a notice of opposition against the above-identified patent. Form 2300.1 mentioned N.V. Nutricia as opponent (section III), with the box in section VII ("Facts and arguments ... are submitted herewith on a separate sheet") being ticked. Attached was a document "Facts and Arguments" signed by the same attorney. In the first paragraph of page 1 of this document, it was stated: "On behalf of Campina Nederland Holding BV, the Netherlands, I hereby file opposition to European Patent No. 1 605 772 B1 ...". This document contained a reference to "the enclosed EPO form 2300" (second paragraph of page 1).
III. By letter of 12 June 2008, another representative from the same law firm informed the EPO that the name N.V. Nutricia given in form 2300.1 was erroneous and should actually read Campina Nederland Holding B.V. The representative requested that the name of the opponent be accordingly corrected to Campina Nederland Holding B.V under Rule 139 EPC.

T 445/08 - True intentions to be confirmed


This appeal is the referring case of G 1/12, and shows the Board applying the answers of G 1/12.

Catchwords:
  • If the notice of appeal is to be considered in the context of the file history, the true intention needs to be confirmed by external facts and evidence at least to prevent that requirements such as those of Article 107 EPC be circumvented (point 9).
  • In applying Rule 139 EPC to a party's request to correct a mistake in the notice of appeal in respect of the identity of the appellant, the principle of legal certainly needs to be taken into consideration (point 10).
Background / Summary of Facts and Submissions
I. The appeal lies from the decision of the Opposition Division, posted on 28 December 2007, revoking European patent No 1140330.

II. The (registered) patent owner was Zenon Technology Partnership, The Corporation Trust Company Corporation Trust Centre 1209 Orange Street, Wilmington, DE 19801/US (the patent had been acquired from Zenon Environmental Inc, 845 Harrington Court Burlington Ontario L7N 3P3 Canada, by an assignment registered by the EPO on 30 May 2006).

III. A notice of appeal, dated 8 February 2008 but received on 15 February 2008, was filed, reading:

"European Patent No 1140330 (99955620.2-062)

Zenon Technology Partnership

We hereby give Notice of Appeal (underlined by the Appellant) against the decision of the Examination Division [sic] dated 28 December 2007 to refuse the above patent application [sic]. Cancellation of the decision in its entirety is requested so that the patent may be maintained?.

The name, address and nationality of the Appellant is (emphasis by the Board):

ZENON ENVIRONMENTAL INC

845 Harrington Court

Burlington

Ontario L7N 3P3

Canada

ZENON ENVIRONMENTAL INC is a Canadian Corporation.

In the event that the Board of Appeal wishes to make a decision detrimental to the Applicant's [sic] rights at any time, it is hereby requested that Oral Proceedings be held to discuss the matter."

The procedural steps after the filing of the notice of appeal

IV. On a communication dated 7 March 2008 notifying the parties of the commencement of the appeal proceedings, the Registrar of the Board added the following handwritten statement: "the appeal was filed in the name of ZENON ENVIRONMENTAL INC (underlined by the Registrar). The patentee is here registered as ZENON TECHNOLOGY PARTNERSHIP (underlined by the Registrar). Therefore the patentee is asked to clarify the situation."

V. The Appellant and the Respondent both reacted with letters dated 13 March 2008.

The Appellant wrote "... the appeal should of course have been filed in the name of the current proprietor, i.e. Zenon Technology Partnership (underlined by the Appellant). I apologise for the confusion and respectfully request the correction".

The Respondent requested that the appeal be rejected as inadmissible, as it had been lodged by a legal entity other than the adversely affected (entitled) party.

T 1164/11 - Use the force




This Examination appeal concerns a medical apparatus for cutaneous administration of medicaments, i.e., through the skin. The main claim in the appeal reads:
 
"A medical apparatus for cutaneous administration of medicaments comprising:
- a supporting frame (100);
- an energy emitter (9) in engagement with the frame (100) and active on the molecules of at least one medicament to cause penetration of same into a skin region to be treated (10); (...) said energy emitter (9) being an electromagnetic wave generator (11) emitting a laser light of a wavelength comprised in the range of 600 to 650 nm."

The board has its doubts whether such a electromagnetic wave generator can really  be  active on the molecules of a medicament to cause penetration into a skin region. The board  evaluates if there is a plausible explanation of the claimed effect and, in the absence thereof, the available evidence.

T 0021/09 - Hear, hear!


The fundamental right to be heard... 
In this decision following opposition the board considers the decision from the OD not to allow additional arguments and experimental evidence as a response to the preliminary opinion just before oral proceedings a violation of the right to be heard under Art 113(1) EPC. It appears that the board was especially unhappy with the fact that the OD failed to address the issue of late-filing and the submission of the evidence it in the minutes of the oral proceedings. The board considers it a fundamental deficiency that there is an absence of reasoning in the decision concerning the experimental evidence filed by the proprietor in support of its line of argument on inventive step, and refers a.o. to decision T 0135/96 of 20 January 1997. 

Summary of Facts and Submissions
I. European patent No. 1 185 695 with the title "Process for high throughput DNA methylation analysis" was granted on European patent application No. 00928969.5, which was filed as international application under the PCT and published as WO 00/70090 (in the following "the application as filed"). The patent was granted with 21 claims.
II. Two oppositions were filed based on the grounds that the claimed subject-matter lacks novelty and inventive step (Article 100(a) in conjunction with Articles 54 and 56 EPC), and extends beyond the content of the application as filed (Article 100(c) EPC), and that the invention as claimed is not disclosed in the patent in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art (Article 100(b) EPC).
III. Opponent 01 withdrew its opposition during the opposition proceedings.
IV. By a decision of an opposition division of the European Patent Office under Articles 101(2),(3)(b) EPC posted on 20 November 2008, the patent was revoked. The opposition division found that the subject-matter of the amended claims according to the main request then on file lacked an inventive step, and that the amendments introduced into the claims according to the second auxiliary request then on file offended against Article 123(2) EPC. A set of claims filed during the oral proceedings as first auxiliary request was not admitted into the proceedings.
V. The patent proprietor (appellant) lodged an appeal against the decision of the opposition division. Together with its statement of grounds of appeal, the appellant submitted a new set of amended claims (claims 1 to 16) "as the main request". The appellant requested that the decision under appeal be set aside and the case be remitted to the opposition division on the grounds that its right to be heard had been violated in opposition proceedings. As a subsidiary request, the appellant requested that the decision under appeal be set aside and the patent be maintained on the basis of the set of claims filed with the statement of grounds of appeal.
VI. The opponent (respondent) replied to the statement of grounds of appeal and requested that the decision under appeal be upheld, the appellant's request for remittal of the case to the opposition division be denied and the outstanding issues be heard by the board. As a subsidiary request, the respondent requested oral proceedings.
VII. By a communication of the board pursuant to Rule 100(2) EPC, the parties were informed that, in spite of being of the provisional opinion that the opposition proceedings suffered from a fundamental procedural deficiency, the board was disinclined to remit the case to the opposition division because the remittal would probably lead to a substantial delay in the procedure. The parties were given the opportunity to submit observations on the issue of remittal.
VIII. The appellant replied to the board's communication maintaining its request for remittal. Further, it requested oral proceedings pursuant to Article 116(1) EPC if the board intended to reject the request for remittal, and reimbursement of the appeal fee in accordance with Rule 103(1)a) EPC.
IX. In its reply to the communication, the respondent submitted further arguments in support of its view that there had been no procedural violation in opposition proceedings. The respondent agreed with the board's provisional opinion that the case should not be remitted to the opposition division.
X. The board summoned the parties to oral proceedings. In a communication under Article 15(1) of the Rules of Procedure of the Boards of Appeal (RPBA) attached to the summons, the board indicated that the issues to be discussed at the oral proceedings were whether or not there had been a fundamental procedural deficiency in opposition proceedings and, if so, whether or not remittal of the case was justified. It was advanced that, if either of these two issues were decided by the board in the negative, further oral proceedings would have to be scheduled for discussion of the outstanding procedural and substantive issues.
XI. On 7 April 2014, the respondent informed the board that it would not be represented at the oral proceedings. It maintained its request that the case not be remitted to the opposition division, and relied on comments presented in writing.
XII. The oral proceedings were cancelled.
[...]
XIV. The submissions made by the appellant in writing that relate to issues relevant to this decision, were essentially as follows:
Violation of the right to be heard - Article 113(1) EPC
In opposition proceedings, the patent proprietor's right to the be heard had been violated. The opposition division had failed to consider not only experimental data submitted in preparation of the oral proceedings, but also a key argument with respect to one of the two embodiments claimed. Moreover, the opposition division had refused to admit a set of claims submitted as first auxiliary request during the oral proceedings.
[...]
Remittal to the opposition division
The violation of the right to be heard constituted a fundamental procedural deficiency which, pursuant to Article 11 of the Rules of Procedure of the Boards of Appeal, required remittal of the case. If the board were to take a final decision on the case, the appellant would be deprived of the right to a properly reasoned decision by the opposition division in which the arguments and experimental evidence submitted in support of an inventive step were taken into account.
XV. The submissions made by the respondents in writing concerning issues relevant to this decision, may be summarized as follows:
Violation of the right to be heard - Article 113(1) EPC
The patent proprietor's right to be heard had not been violated in opposition proceedings. The issues of added matter, novelty and inventive step had been considered at length during the course of the oral proceedings before the opposition division. The experimental data submitted by the patent proprietor had not been overlooked. The proprietor had referred to these data during the course of the oral proceedings, and, as was apparent from section 5.4.1 of the decision under appeal, in particular the first full sentence at the top of page 16, and the statements on page 17, the opposition division had taken into account the data, but considered them to be of no assistance in determining inventive step. The decision under appeal was properly reasoned in that it accurately reflected the points that had been made during the course of the oral proceedings.
[...]
The amendment introduced into the claims of the first auxiliary request did not limit the scope of the claims, raised questions of clarity under Article 84 EPC and did not clearly address the objections of lack of inventive step.
Remittal to the opposition division
For the sake of procedural efficiency, the case should not be remitted back to the opposition division. The patent proprietor had had a proper opportunity to present its case before the opposition division. Any remittal at this stage would only cause unnecessary delay in the proceedings.
XVI. The appellant requested that the decision under appeal be set aside and the case be remitted to the opposition division for further prosecution. Additionally, the appellant requested reimbursement of the appeal fee. As a subsidiary request, oral proceedings were requested.
XVII. The respondent requested that the appeal be dismissed. Subsidiarily, the respondent requested that the appellant's request for remittal of the case to the opposition division be dismissed.
Reasons for the Decision
Violation of the right to be heard - Article 113(1) EPC
1. The main issue to be decided is whether or not the right to be heard (Article 113 EPC) of the patent proprietor (the present appellant) was violated in opposition proceedings. The appellant substantiated its allegation of a procedural violation arguing that the opposition division not only failed to consider experimental data and a key argument on inventive step submitted with the reply to the summons to oral proceedings, but also refused to admit into the proceedings the set of amended claims filed during the oral proceedings as first auxiliary request (see section 6.3 of the decision under appeal).
2. As regards the experimental data, the appellant referred to the Annexes 9, 8a, 8b and 7c. These Annexes were submitted by the patent proprietor as a reaction to the preliminary opinion of the opposition division on inventive step expressed in the communication dated 15 April 2008 attached to the summons to oral proceedings. In the communication, the opposition division held that none of the technical effects on which the patent proprietor relied in respect of the method of claim 6 as granted (application B) was "... supported by any corresponding experimental data which thus, pursuant established case law (cf. Case Law 5**(th) Ed. 2006, I.D.4.2), cannot be taken into consideration for the assessment of inventive step" (see paragraph bridging pages 18 and 19 of the communication).
3. According to the appellant, Annex 9 ("Evidence showing inventiveness of Application B") showed the technical performance and the biological and clinical relevance of the claimed method by reference to independent scientific publications of third parties and publications of the patent proprietor, as well as by experimental data (see sections 1.3 and 2). Prima facie, Annex 9 has evidential value for the ability of the method to discriminate between neighbouring methylation levels, in particular between low methylation levels (see section 1.3.3 of Annex 9). Additionally, Annex 9 shows that, applying the method defined as "application B", small amounts of DNA can be detected independently from DNA concentration (see section 1.3.1) with good repeatability (see section 1.3.2).
4. The evidence in Annexes 7c, 8a and 8b relates to application D. Annex 7c presents the results of experiments aimed at the detection of methylation patterns, and Annexes 8a and 8b show the results of comparative experiments in which the claimed method is compared to methods known in the prior art, in particular the Sunrise**(©) (Annex 8a) and the SybrGreen**(TM) technologies (Annex 8b). Prima facie, the experiments show a higher specificity of the claimed method.
5. Annexes 9, 8a, 8b and 7c are not mentioned in the decision under appeal. Nor are the specific experimental data provided therein discussed in the decision in connection with the issue of inventive step. Contrary to the respondent's view, the first full sentence on the top of page 16 of the decision under appeal does not relate to the experimental evidence in the Annexes in question, but only to that in Annex I, which had been filed by the proprietor on 21 November 2007 in response to the notices of opposition. As regards the statements on page 17 of the decision ("The other two technical effects are not supported by any corresponding experimental data ..."), it is not clear to the board whether the opposition division, when arriving at this finding, disregarded the experimental evidence in the Annexes in question, in particular Annex 9, or whether it considered it, but found it not to support the alleged technical effects for reasons not specified in the decision.
6. The minutes of the oral proceedings before the opposition division dated 20 November 2008 do not reflect any discussion on the experimental evidence submitted by the patent proprietor in preparation of the oral proceedings. It is, however, stated in section 3 of the minutes that documents (42) to (75) - which were filed by the patent proprietor with the same submission as the Annexes - were considered to be late-filed, and that the discussion on whether or not they were admitted into the proceedings was postponed. Whether or not the same applied to the Annexes in question, which are not specifically mentioned in this passage, is unclear. In any case it is noted that a discussion on the admission of late-filed evidence - if it took place - has not been recorded in the minutes of the oral proceedings, and that documents (42) to (75) - like the Annexes in question - are not mentioned in the reasons given by the opposition division for its findings on inventive step.
7. Under these circumstances, two possibilities arise: either the opposition division disregarded the experimental evidence in the Annexes in question as late-filed, or it may have considered it, but failed to give proper reasons in its decision as to why this evidence does not support the technical effects on which the patent proprietor relied in its line of argument on inventive step. In the first case, not only the patent proprietor has not been heard on the issue of admission of the evidence into the opposition proceedings, but, more importantly, the decision is absolutely silent about it. In the second case, the decision under appeal suffers from a severe deficiency in the reasons given by the opposition division for the adverse findings on inventive step.
8. In either case, the decision cannot be regarded as being in conformity with Rule 111(2) EPC. Since the opposition division refused the main request for lack of inventive step, the absence of reasoning in the decision concerning the experimental evidence filed by the patent proprietor in support of its line of argument on inventive step is, in accordance with the jurisprudence of the Boards of Appeal (see, inter alia, decision T 135/96 of 20 January 1997), a fundamental deficiency.
9. The question whether or not the patent proprietor expressly requested admission of the experimental evidence during the oral proceedings is not regarded by the board as a circumstance that would mitigate the severity of the violation. Since the evidence was submitted by the patent proprietor in preparation of the oral proceedings and in clear response to the opposition division's communication, it had to be assumed that the proprietor's intention was to have the experimental evidence admitted into the proceedings and considered by the opposition division.
10. Summarising the above, the board concludes that the opposition division's failure to either consider the experimental evidence brought forward by the patent proprietor, or give reasons as to why it was not admitted into the proceedings, or did not support the purported effects, violated the patent proprietor's right to be heard. Since there is a causal link between the procedural deficiency and the final adverse decision on inventive step, the procedural defect is decisive and hence fundamental.
11. In view of these findings, there is no need to consider the appellant's further allegation of a procedural violation based on the non-admission of the first auxiliary request filed during the oral proceedings.
Remittal to the opposition division
12. According to Article 11 of the Rules of Procedure of the Boards of Appeal, a board shall remit a case to the department of first instance if fundamental deficiencies are apparent in the first instance proceedings, unless special reasons present themselves for doing otherwise.
13. In the present case, the respondent argued that remittal to the opposition division would entail a delay in reaching a final decision.
14. The board shares the view of the competent board in decision T 48/00 of 12 June 2002 (see section 11 of the Reasons) that a delay of the final decision caused by the remittal is an insufficient reason not to order remittal. The fundamental right of an appellant to a fair hearing before the opposition division must overweigh any advantage that might accrue to the respondent by having the board of appeal deal fully with the case rather than remit it (see decision T 914/98 of 22 September 2000; section 3 of the Reasons).
15. For these reasons, the board decides to remit the case to the opposition division for further prosecution.
[...]
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division for further prosecution.
3. The appeal fee is to be reimbursed.

This decision has European Case Law Identifier: ECLI:EP:BA:2014:T002109.20141113. The whole decision can be found here. The file wrapper can be found here. Photo obtained via Flickr.

T 2184/10 - On second thought, not so clear





This appeal reversed the opposition division's decision on clarity after the opponent introduced evidence to show lack of clarity.


Claim 1 of the main request concerned a method for conveying resistance to beet necrotic yellow vein virus (BNYVV) to a sugar beet plant. The claim requires that "said resistance is a durable resistance and in which the virus does not replicate"

The durable resistance feature was first introduced in an auxiliary request filed during the oral proceedings of the opposition. One might have some reservation about what durable means exactly, but the opposition division had no problems with clarity. In the grounds for the decision the opposition division had this to say about the clarity of this term:

(...) a reference to the durable resistance must be understood as a reference to the properties of the plants obtained by said method. Any other interpretation would be technically meaningless. The Opposition Division also concluded that the term "durable resistance" was clear to the skilled person, i. e. it referred to resistance during essentially the whole life of a plant.

 And I guess that is not unreasonable. Each field has its own terms, and I guess durable resistance can be distinguished in practice from other types of resistance. In fact the opposition division found the Claim not inventive because, inter alia, it is "common practice for the skilled person to look for the best, i. e. complete and durable, resistance and to screen for the complete absence of virus replication."

In appeal, the opponent introduced a new document, which gives a nuanced view of durable resistance, which seems to have swayed the board.


Reasons for the Decision
(...)
Main Request
Article 84 EPC; admissibility of document D19

5. In comparison to claim 1 as granted, the Main Request requires the DNA fragment used in step (a) of claim 1 to be "of at least 35 nucleotides" (instead of 15 nucleotides) and the conveyed BNYVV resistance to be "a durable resistance and in which the virus does not replicate" (cf. point VIII supra). The term "durable resistance" was objected under Article 84 EPC for lack of clarity in the opposition proceedings and the opposition division decided that the term fulfilled the requirements of this article (cf. page 12, point 4.1.1 of the decision under appeal).

6. In reply to the appellant's Grounds of Appeal, the respondent maintained the objection of lack of clarity for the term "durable resistance" and filed document D19 to support its arguments (cf. point III supra). Document D19 is a general review which is, as its title indicates: "A critical analysis of durable resistance", clearly concerned with the objected term. Since the feature in claim 1 comprising the objected term was introduced for the first time with the filing of an auxiliary request at the oral proceedings before the opposition division, the board agrees with the respondent that there was no opportunity to file document D19 at an earlier stage of the proceedings (cf. point XIV supra).

7. Thus, the board, in exercise of its discretion, decides to admit document D19 into the appeal proceedings (Article 12(4) RPBA).

8. As for the objection under Article 84 EPC for lack of clarity of the term "durable resistance", the board notes the following:

8.1 As argued by the respondent (cf. point XIV supra), there is no definition for this term in the patent. In fact, several terms are used in the patent, such as "total resistance" and "absolute resistance" (cf. page 2, paragraph [0011], line 56, page 4, paragraph [0028], lines 44, 49 and 50, page 7, paragraph [0048], line 3 of the patent). However, the patent does not define the precise meaning of each of these terms. In the decision under appeal, the opposition division considered the term "durable resistance" to be clear to a skilled person and it further defined this term as meaning a "resistance during essentially the whole life of a plant" without specifying any other limitation and/or requirement (cf. page 12, point 4.1.1 of the decision under appeal).

8.2 This definition closely resembles the definition of this term given in document D19, namely "a resistance that remains effective during its prolonged and widespread use in an environment favorable to the disease" (cf. page 309, first paragraph of document D19). However, document D19 refers to several elements for measuring and/or testing a "durable resistance", including time (long), area (large), number of pathogen races or subtypes, disease pressure, etc. and it further differentiates between the effectiveness or level of resistance and its durability. Indeed, it is explicitly stated that "(t)here is clearly a subjective element in the decision to describe the resistance of a cultivar as durable", further adding that "(i)n many instances the decision will depend partly on the relative performance of other cultivars" (emphasis added by the board) (cf. page 310, third paragraph of document D19).

8.3 The appellant, in its reply to the board's communication pursuant to Article 15(1) RPBA, argued that a "demonstrated durable resistance against BNYVV" is "evidenced by its progeny (i.e. with stable inherited genome insertion)" (cf. inter alia, page 10, fourth paragraph, page 15, last but one paragraph of the appellant's letter dated 18 April 2014; point VI supra). This is also evident from the subject-matter exemplified in the patent, where the bioassay for BNYVV resistance was carried out using the transgenic F1 seeds (cf. page 6, Examples 2 and 3 of the patent). Although, as stated by the appellant (cf. point XIII supra), the definition of the term "durable resistance" given in document D19 and by the opposition division in the decision under appeal did not exclude this further requirement, it did not necessarily include it.

9. In the light of the factual situation described above and under specific consideration of the arguments presented by the appellant itself, the board concludes that the term "durable resistance" has no generally accepted meaning in the here relevant technical field and is thus open to interpretation. As such it is ambiguous and renders the scope of claim 1 unclear. Thus, the Main Request does not fulfil the requirements of Article 84 EPC.
 

This decision has European Case Law Identifier:  ECLI:EP:BA:2014:T218410.20140520. The whole decision can be found here. The file wrapper can be found here. Photo by  Derrick Tyson
obtained via Flickr.